Additionally, based on the work presented here, combinatorial therapies targeting geminin through inhibiting c-Abl with imatinib plus CBP inhibitor and/or drugs that activate SIRT1 and/or inhibitors Ac-HMGB1 secretion or binding to RAGE could be pursued as valid therapies to prevent MSCs recruitment and enhancement of GemOE/TNBC tumor aggressiveness. This evidence concerns the gene ABL1 and neoplasm.